Andreas Rimner
New York, NYNPI 1508060963
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,871 of the $69,239 with a category attached, or 95.1%. 4 manufacturers reported payments, led by AstraZeneca at 48.3% of the total. Reporting peaked in 2020 at $22,695 and has fallen 91.7% since, to $1,888 in 2024.
Across 50 payments — averaging $1384.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$33K
- Merck$19K
- Astrazeneca UK Limited$13K
- Boehringer Ingelheim$4K
Across 46 payments — averaging $227,975 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$9M
- Merck$690K
- Boehringer Ingelheim$427K
- Pfizer$258K
- Varian Medical Systems, Inc.$107K
What the payments were for
- Consulting fees$65,87195%
- Travel & lodging$2,3183%
- Food & beverage$1,0512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $33,414 |
| Merck | 12 | $19,090 |
| Astrazeneca UK Limited | 5 | $12,835 |
| Boehringer Ingelheim | 1 | $3,900 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.